The range of indications for the use of immune checkpoint inhibitors is presently expanding. The paper describes a clinical case of the development of finger bone necrosis in a patient with Hodgkin’s lymphoma during therapy with checkpoint inhibitors. During treatment, the patient developed ischemia of the fifth finger of the left hand and the second finger of the right hand. Because of the suspected autoimmune nature of the complication, infliximab, prednisone, clopidogrel, and trental were prescribed by the decision of the physician’s conference. After the treatment, the condition of the fingers generally improved; however, dry gangrene of the distal phalanx of the fifth finger of the left hand developed. This case demonstrates the need for early recognition and rapid intervention when immune-mediated adverse events occur with the use of immune checkpoint inhibitors to correct them as quickly and efficiently as possible.